Timeline of Key Regulatory and Legal Events: September 9, 2025 FDA Warning Letter: The FDA issued a warning letter to Hims & Hers Health on September 9, 2025, finding false or misleading claims on its website about compounded semaglutide and tirzepatide, including phrases such as Same active ingredient as Ozempic and Wegovy and Clinically proven ingredients, which imply the compounded products are the same as FDA-approved drugs when they are not
transfers allowed only in full-month increments or as credit toward RX or RX (+) Program Bonus injections must be used within 2 months of offer end dont miss out!
23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods
Regarding odor assessment, sample Cformulated with 20% carnitinereceived the highest scores, suggesting that elevated carnitine concentrations may intensify aromatic perception
If your biology is resistant to the initial doses, it is a clinical hurdle to be discussed with a provider, not a personal failing
Mant CT, Chen Y, Hodges RS